Functional Role of 5-HT2 Receptors in the Regulation of Sleep and Wakefulness in the Rat

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 1989 Jan 1

PMID 2524856

Citations 23

Authors

C Dugovic

A Wauquier

J E Leysen

R Marrannes

P A Janssen

Affiliations

Soon will be listed here.

Abstract

Recently developed agents specifically acting on different 5-hydroxytryptamine (5-HT) receptor populations were used to analyze the functional role of 5-HT2 receptor subtypes in the sleep-wakefulness cycle of the rat. The 5-HT2 receptor antagonist ritanserin injected intraperitoneally (IP) (0.04-2.5 mg/kg) induced an increase in deep slow wave sleep (SWS2) duration at the expense of wakefulness (W), light slow wave sleep (SWS1) and paradoxical sleep (PS). The stimulation of 5-HT2 receptors by 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) produced a dose-related increase in W and a dose-dependent decrease in both SWS2 and PS. Pretreatment with ritanserin (0.16-2.5 mg/kg) or with cinanserin (2.5-5 mg/kg), another 5-HT2 receptor antagonist, dose-dependently reversed the W enhancement and the SWS2 deficit produced by DOM, but not the PS deficit. Sleep-wakefulness alterations (increase in W and SWS1 combined with a suppression of SWS2 and PS) observed after IP injection of two putative 5-HT1 receptor agonists, 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) (2.5 mg/kg) and 5-methoxy-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (RU 24969) (0.63 mg/kg), were not modified by ritanserin pretreatment (0.16-2.5 mg/kg). These results further support the hypothesis that the serotonergic system plays an active role in the regulation of the sleep-wakefulness cycle in the rat and that 5-HT2 receptors are involved in this action. In addition, it is suggested that 5-HT1 receptor subtypes are unlikely to interact with 5-HT2 receptors in the sleep-wakefulness modulation mediated through 5-HT2 receptors.

Citing Articles

Terpenoids derived from oil enhance sleep by modulating neurotransmitter signaling in mice.

Sun M, Li M, Cui X, Yan L, Pei Y, Wang C Heliyon. 2024; 10(5):e26979.

PMID: 38463787 PMC: 10923681. DOI: 10.1016/j.heliyon.2024.e26979.

A Cross-Sectional Study on the Relationship Among Cytokines, 5-HT2A Receptor Polymorphisms, and Sleep Quality of Non-manual Workers in Xinjiang, China.

Wang J, Gao X, Gao P, Liu J Front Psychiatry. 2022; 13:777566.

PMID: 35463508 PMC: 9019505. DOI: 10.3389/fpsyt.2022.777566.

Agomelatine treatment corrects impaired sleep-wake cycle and sleep architecture and increases MT receptor as well as BDNF expression in the hippocampus during the subjective light phase of rats exposed to chronic constant light.

Tchekalarova J, Kortenska L, Ivanova N, Atanasova M, Marinov P Psychopharmacology (Berl). 2019; 237(2):503-518.

PMID: 31720718 DOI: 10.1007/s00213-019-05385-y.

Additive effect of 5-HT2C and CB1 receptor blockade on the regulation of sleep-wake cycle.

Bogathy E, Papp N, Tothfalusi L, Vas S, Bagdy G BMC Neurosci. 2019; 20(1):14.

PMID: 30894126 PMC: 6427841. DOI: 10.1186/s12868-019-0495-7.

Ablation of Central Serotonergic Neurons Decreased REM Sleep and Attenuated Arousal Response.

Iwasaki K, Komiya H, Kakizaki M, Miyoshi C, Abe M, Sakimura K Front Neurosci. 2018; 12:535.

PMID: 30131671 PMC: 6090062. DOI: 10.3389/fnins.2018.00535.

References

Sallanon M, Buda C, Janin M, Jouvet M . 5-HT antagonists suppress sleep and delay its restoration after 5-HTP in p-chlorophenylalanine-pretreated cats. Eur J Pharmacol. 1982; 82(1-2):29-35. DOI: 10.1016/0014-2999(82)90549-0. View

Leysen J, Gommeren W, Van Gompel P, Wynants J, Janssen P, Laduron P . Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist. Mol Pharmacol. 1985; 27(6):600-11. View

Oswald I, Adam K, Spiegel R . Human EEG slow-wave sleep increased by a serotonin antagonist. Electroencephalogr Clin Neurophysiol. 1982; 54(5):583-6. DOI: 10.1016/0013-4694(82)90044-x. View

McGinty D, Harper R . Dorsal raphe neurons: depression of firing during sleep in cats. Brain Res. 1976; 101(3):569-75. DOI: 10.1016/0006-8993(76)90480-7. View

Gozlan H, El Mestikawy S, PICHAT L, Glowinski J, Hamon M . Identification of presynaptic serotonin autoreceptors using a new ligand: 3H-PAT. Nature. 1983; 305(5930):140-2. DOI: 10.1038/305140a0. View

Idzikowski C, Mills F, Glennard R . 5-Hydroxytryptamine-2 antagonist increases human slow wave sleep. Brain Res. 1986; 378(1):164-8. DOI: 10.1016/0006-8993(86)90299-4. View

Enjalbert A, Bourgoin S, Hamon M, Adrien J, Bockaert J . Postsynaptic serotonin-sensitive adenylate cyclase in the central nervous system. I. Development and distribution of serotonin and dopamine-sensitive adenylate cyclases in rat and guinea pig brain. Mol Pharmacol. 1978; 14(1):2-10. View

Leysen J, Awouters F, Kennis L, Laduron P, Vandenberk J, Janssen P . Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors. Life Sci. 1981; 28(9):1015-22. DOI: 10.1016/0024-3205(81)90747-5. View

Gaillard J . Biochemical pharmacology of paradoxical sleep. Br J Clin Pharmacol. 1983; 16 Suppl 2:205S-230S. PMC: 1428227. DOI: 10.1111/j.1365-2125.1983.tb02294.x. View

10.

Tricklebank M, Forler C, Fozard J . The involvement of subtypes of the 5-HT1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propylamino)tetralin in the rat. Eur J Pharmacol. 1984; 106(2):271-82. DOI: 10.1016/0014-2999(84)90714-3. View

11.

Titeler M, Herrick K, Lyon R, McKenney J, Glennon R . [3H]DOB: a specific agonist radioligand for 5-HT2 serotonin receptors. Eur J Pharmacol. 1985; 117(1):145-6. DOI: 10.1016/0014-2999(85)90486-8. View

12.

Laguzzi R . [Effects of the intraventricular injection of methiothepin and methergoline on the sleep of rats]. C R Seances Soc Biol Fil. 1981; 175(2):160-3. View

13.

Puizillout J, Daszuta A, Seyfritz N, Ternaux J . Release of endogenous serotonin from "encéphale isolé" cats. II - Correlations with raphe neuronal activity and sleep and wakefulness. J Physiol (Paris). 1979; 75(5):531-7. View

14.

Fuxe K, Kiianmaa K . 5-Hydroxytryptamine neurons and the sleep-wakefulness cycle. Effects of methergoline and zimelidine. Neurosci Lett. 2009; 8(1):55-8. DOI: 10.1016/0304-3940(78)90097-6. View

15.

Jouvet M . Biogenic amines and the states of sleep. Science. 1969; 163(3862):32-41. DOI: 10.1126/science.163.3862.32. View

16.

Pedigo N, Yamamura H, Nelson D . Discrimination of multiple [3H]5-hydroxytryptamine binding sites by the neuroleptic spiperone in rat brain. J Neurochem. 1981; 36(1):220-6. DOI: 10.1111/j.1471-4159.1981.tb02397.x. View

17.

Colpaert F, Meert T, NIEMEGEERS C, Janssen P . Behavioral and 5-HT antagonist effects of ritanserin: a pure and selective antagonist of LSD discrimination in rat. Psychopharmacology (Berl). 1985; 86(1-2):45-54. DOI: 10.1007/BF00431683. View

18.

Hedner T, Pettersson A, Persson B . Chronic 5-HT2-receptor blockade by ritanserin does not reduce blood pressure in patients with essential hypertension. Acta Med Scand. 1987; 222(4):307-10. DOI: 10.1111/j.0954-6820.1987.tb10676.x. View

19.

Shannon M, Battaglia G, Glennon R, Titeler M . 5-HT1 and 5-HT2 binding properties of derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane (2,5-DMA). Eur J Pharmacol. 1984; 102(1):23-9. DOI: 10.1016/0014-2999(84)90333-9. View

20.

Leysen J, NIEMEGEERS C, Tollenaere J, Laduron P . Serotonergic component of neuroleptic receptors. Nature. 1978; 272(5649):168-71. DOI: 10.1038/272168a0. View